Guggenheim Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)

Research analysts at Guggenheim assumed coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $12.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 310.96% from the company’s previous close.

Several other research analysts have also commented on CMPX. Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective for the company. Jefferies Financial Group upped their target price on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $2.92 on Monday. Compass Therapeutics has a one year low of $0.76 and a one year high of $4.08. The firm has a market capitalization of $401.76 million, a P/E ratio of -7.89 and a beta of 1.17. The business has a fifty day moving average price of $2.43 and a 200-day moving average price of $1.89.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CMPX. MPM Bioimpact LLC lifted its stake in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after acquiring an additional 2,926,002 shares during the period. Enavate Sciences GP LLC bought a new position in Compass Therapeutics in the 4th quarter worth $11,293,000. Tang Capital Management LLC lifted its position in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the period. Rock Springs Capital Management LP boosted its stake in shares of Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock valued at $8,380,000 after purchasing an additional 150,336 shares in the last quarter. Finally, Blue Owl Capital Holdings LP increased its position in shares of Compass Therapeutics by 2.6% during the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock valued at $4,284,000 after buying an additional 75,000 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.